131 related articles for article (PubMed ID: 38709106)
1. Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.
Adair A; Tan LL; Feng J; Girkin J; Bryant N; Wang M; Mordant F; Chan L-J; Bartlett NW; Subbarao K; Pymm P; Tham W-H
J Virol; 2024 Jun; 98(6):e0053124. PubMed ID: 38709106
[TBL] [Abstract][Full Text] [Related]
2. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
3. The dominance of human coronavirus OC43 and NL63 infections in infants.
Dijkman R; Jebbink MF; Gaunt E; Rossen JW; Templeton KE; Kuijpers TW; van der Hoek L
J Clin Virol; 2012 Feb; 53(2):135-9. PubMed ID: 22188723
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses.
Sampson AT; Heeney J; Cantoni D; Ferrari M; Sans MS; George C; Di Genova C; Mayora Neto M; Einhauser S; Asbach B; Wagner R; Baxendale H; Temperton N; Carnell G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452443
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel Neutralizing Epitope on the N-Terminal Domain of the Human Coronavirus 229E Spike Protein.
Shi J; Shi Y; Xiu R; Wang G; Liang R; Jiao Y; Shen Z; Zhu C; Peng G
J Virol; 2022 Feb; 96(4):e0195521. PubMed ID: 34908442
[TBL] [Abstract][Full Text] [Related]
7. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
8. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients.
Gerna G; Campanini G; Rovida F; Percivalle E; Sarasini A; Marchi A; Baldanti F
J Med Virol; 2006 Jul; 78(7):938-49. PubMed ID: 16721849
[TBL] [Abstract][Full Text] [Related]
9. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines.
Sayama Y; Okamoto M; Saito M; Saito-Obata M; Tamaki R; Joboco CD; Lupisan S; Oshitani H
Sci Rep; 2023 Feb; 13(1):2310. PubMed ID: 36759702
[TBL] [Abstract][Full Text] [Related]
12. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus HKU1 and other coronavirus infections in Hong Kong.
Lau SK; Woo PC; Yip CC; Tse H; Tsoi HW; Cheng VC; Lee P; Tang BS; Cheung CH; Lee RA; So LY; Lau YL; Chan KH; Yuen KY
J Clin Microbiol; 2006 Jun; 44(6):2063-71. PubMed ID: 16757599
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
15. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
[TBL] [Abstract][Full Text] [Related]
16. Pivotal Role of Receptor-Interacting Protein Kinase 1 and Mixed Lineage Kinase Domain-Like in Neuronal Cell Death Induced by the Human Neuroinvasive Coronavirus OC43.
Meessen-Pinard M; Le Coupanec A; Desforges M; Talbot PJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795420
[TBL] [Abstract][Full Text] [Related]
17. Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43.
Boonyaratanakornkit J; Sholukh AM; Gray M; Bossard EL; Ford ES; Corbett KS; Corey L; Taylor JJ
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696505
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.
Yang Y; Li F; Du L
J Nanobiotechnology; 2024 May; 22(1):304. PubMed ID: 38822339
[TBL] [Abstract][Full Text] [Related]
19. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals.
Adami FL; de Castro MV; Almeida BDS; Daher IP; Yamamoto MM; Souza Santos K; Zatz M; Naslavsky MS; Rosa DS; Cunha-Neto E; de Oliveira VL; Kalil J; Boscardin SB
Front Immunol; 2024; 15():1396603. PubMed ID: 38846944
[TBL] [Abstract][Full Text] [Related]
20. The ns12.9 Accessory Protein of Human Coronavirus OC43 Is a Viroporin Involved in Virion Morphogenesis and Pathogenesis.
Zhang R; Wang K; Ping X; Yu W; Qian Z; Xiong S; Sun B
J Virol; 2015 Nov; 89(22):11383-95. PubMed ID: 26339053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
